Le Lézard
Classified in: Health
Subjects: CCA, FVT

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2021 Results: November 4, 2020


BOSTON, Oct. 6, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish second quarter fiscal year 2021 financial results at 6:00 am EDT on Wednesday, November 4, 2020. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am EDT on November 4, 2020. 

The call can be accessed with the following information:

U.S. / Canada toll free (877) 848-8880; International (716) 335-9512
Conference ID required for access: 3899118

A live webcast of the call can be accessed on Haemonetics' investor relations website. Webcast Link: https://edge.media-server.com/mmc/p/ge7vnpw8

Webcast replay will be available from November 4, 2020 11:00 am to November 12, 2020 11:00 am EDT.

About Haemonetics

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions for customers to help them improve patient care and reduce the cost of healthcare. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.  

Investor Contact:   

Media Contact:

Olga Guyette, Director-Investor Relations 

Carla Burigatto, VP-Global Communications

(781) 356-9763                 

(781) 348-7263

[email protected]   

[email protected]

 

SOURCE Haemonetics Corporation


These press releases may also interest you

at 20:31
Club Studio Opens New Location in Kingwood, Texas
Fitness International, LLC opened a new Club Studio location in Kingwood, Texas. The new 40,000 square foot club features five innovative boutique fitness studios that were carefully curated to create a unique experience, along with recovery services...

at 19:35
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...

at 19:00
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...

at 18:36
Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off
Inhibrx, Inc. ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of...

at 17:55
Asia Green Biotechnology Corp. Announces Extension of Management Cease Trade Order
Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the...

at 17:53
DID YOU PURCHASE AND/OR INGEST U-DREAM IN CANADA ON OR AFTER AUGUST 18, 2014?
The following statement is being issued by Rice Harbut Elliott LLP regarding the Ruckman v. Biotrade Canada Ltd. et al. lawsuit: All persons in Canada who purchased or ingested U-Dream on or after August 18, 2014 (the "Class" or "Class Members")...

More news about Health...


News published on and distributed by: